Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PJ009 in Short Bowel Syndrome
NCT06512584Phase 3Active, not recruiting
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of teduglutide in short bowel syndrome (SBS), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Started Sep 2024; status: active, not recruiting.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT06512584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512584.